All nine pancreatic adenocarcinomas harbored exon 2 pathogenic gain‐of‐function variants in KRAS and 6/9 cases had a deleterious loss‐of‐function variant in TP53. The gene discussed is KRAS; the disease is pancreatic adenocarcinoma.